AI주식인사이트AI Stock Insight
B

바이오플러스

099430KOSDAQ기초 의약물질 제조업

57.7 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40
News Sentiment15.7 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but Operating Profit is on a declining trend. Rose 7.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioPlus is a company specializing in the development and sale of medical devices, bio-pharmaceuticals, and bio-cosmetics, leveraging technologies such as MDM and temperature-sensitive materials to enhance product performance. To expand globally, the company has established a foreign subsidiary in Hainan, China, and operates a large-scale factory in Chungcheongbuk, South Korea, focusing on improving profitability.

Number of Employees

187people

Average Salary

60.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
20.79Industry Average 33.456.5Point

Lower than industry avg (good)

PBR
1.66Industry Average 2.034.0Point

In line with industry avg

ROE
11.67Industry Average -4.293.5Point

Well below industry avg

Debt Ratio
6.54Industry Average 6.614.0Point

In line with industry avg

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲19.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼26.1% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 15.2% (declining, 3yr)

Detailed News Sentiment

11 totalPositive 4Neutral 2Negative 0Average Sentiment Score 73.3

Detailed Momentum

52-week position1.0Point

Near 52w low (18%, downtrend)

Current 5,260Won52-week high 8,35052-week low 4,550
1-month return5.0Point

1m +7.57% (rising)

Volume trend3.0Point

Volume flat

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-04-02
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
  • Neutral정기주주총회결과2026-03-30
  • Neutral기업가치제고계획(자율공시)2026-03-30
  • Neutral사업보고서 (2025.12)2026-03-20